CL2008000804A1 - Uso de una sal de cobre enmascarada o recubierta en una composicion farmaceutica para el tratamiento de una enfermedad tratable a traves de una sal de cobre como degeneracion macular; material de capsula digerible. - Google Patents
Uso de una sal de cobre enmascarada o recubierta en una composicion farmaceutica para el tratamiento de una enfermedad tratable a traves de una sal de cobre como degeneracion macular; material de capsula digerible.Info
- Publication number
- CL2008000804A1 CL2008000804A1 CL200800804A CL2008000804A CL2008000804A1 CL 2008000804 A1 CL2008000804 A1 CL 2008000804A1 CL 200800804 A CL200800804 A CL 200800804A CL 2008000804 A CL2008000804 A CL 2008000804A CL 2008000804 A1 CL2008000804 A1 CL 2008000804A1
- Authority
- CL
- Chile
- Prior art keywords
- copper salt
- digerable
- masked
- treatment
- pharmaceutical composition
- Prior art date
Links
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical class [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 title 2
- 239000002775 capsule Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000002780 macular degeneration Diseases 0.000 title 1
- 239000000463 material Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
- A23P20/10—Coating with edible coatings, e.g. with oils or fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07104792A EP1974733A1 (en) | 2007-03-23 | 2007-03-23 | Use of a masked or coated copper salt for the treatment of macular degeneration |
| EP07111322 | 2007-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008000804A1 true CL2008000804A1 (es) | 2008-10-24 |
Family
ID=39477329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200800804A CL2008000804A1 (es) | 2007-03-23 | 2008-03-20 | Uso de una sal de cobre enmascarada o recubierta en una composicion farmaceutica para el tratamiento de una enfermedad tratable a traves de una sal de cobre como degeneracion macular; material de capsula digerible. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20080233182A1 (enExample) |
| EP (1) | EP2124973B1 (enExample) |
| JP (1) | JP2010521534A (enExample) |
| KR (1) | KR101688656B1 (enExample) |
| AR (1) | AR065791A1 (enExample) |
| AU (1) | AU2008231847B2 (enExample) |
| BR (1) | BRPI0809258B8 (enExample) |
| CA (1) | CA2681514C (enExample) |
| CL (1) | CL2008000804A1 (enExample) |
| CO (1) | CO6230993A2 (enExample) |
| DK (1) | DK2124973T3 (enExample) |
| EC (1) | ECSP099700A (enExample) |
| ES (1) | ES2542694T3 (enExample) |
| GT (1) | GT200900251A (enExample) |
| IL (1) | IL201109A (enExample) |
| MA (1) | MA31293B1 (enExample) |
| MX (1) | MX2009010244A (enExample) |
| MY (1) | MY164520A (enExample) |
| NZ (1) | NZ579852A (enExample) |
| PE (1) | PE20090186A1 (enExample) |
| PL (1) | PL2124973T3 (enExample) |
| PT (1) | PT2124973E (enExample) |
| RU (1) | RU2009139002A (enExample) |
| TN (1) | TN2009000387A1 (enExample) |
| TW (1) | TW200904456A (enExample) |
| WO (1) | WO2008116806A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102421422A (zh) | 2009-03-09 | 2012-04-18 | 普罗诺瓦生物医药挪威公司 | 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途 |
| KR101759255B1 (ko) | 2015-09-18 | 2017-07-18 | 한국산업기술대학교산학협력단 | 무촉매 방식 가변경사각을 갖는 나노 구조물 성장 방법 |
| AR118962A1 (es) * | 2019-05-22 | 2021-11-10 | Bayer Consumer Care Ag | Preparaciones de cápsulas de gelatina blanda de vitaminas y minerales que comprenden vitamina c en forma de una sal de ascorbato |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2043487A1 (enExample) * | 1969-05-28 | 1971-02-19 | Commissariat Energie Atomique | |
| US5298237A (en) * | 1992-01-24 | 1994-03-29 | The Trustees Of Columbia University In The City Of New York | Gel composition for reduction of gingival inflammation and retardation of dental plaque |
| US5641512A (en) * | 1995-03-29 | 1997-06-24 | The Procter & Gamble Company | Soft gelatin capsule compositions |
| US20030004043A1 (en) * | 2001-06-27 | 2003-01-02 | Deola James A. | Pivoting backrest for exercise apparatus |
| US20030104043A1 (en) * | 2001-12-03 | 2003-06-05 | Brown Beverly Ann | Topical cream for alleviating spider veins |
| US20050249820A1 (en) * | 2004-05-04 | 2005-11-10 | Akorn, Inc. | Nutritional supplement for the treatment and prevention of macular degeneration |
| US7887847B2 (en) * | 2004-05-08 | 2011-02-15 | Paul Jr Edward L | Nutritional supplement for treatment of ocular diseases |
| US7449196B2 (en) * | 2004-07-09 | 2008-11-11 | Robert Sabin | Anti tumor compositions and methods of use |
| EP1614414A3 (en) * | 2004-07-09 | 2008-07-09 | Robert Sabin | Compositions comprising a copper compound for treatment of mammalian diseases |
| CA2588166A1 (en) * | 2004-11-19 | 2006-05-26 | Martek Biosciences Corporation | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
-
2008
- 2008-03-19 RU RU2009139002/15A patent/RU2009139002A/ru not_active Application Discontinuation
- 2008-03-19 PE PE2008000520A patent/PE20090186A1/es not_active Application Discontinuation
- 2008-03-19 WO PCT/EP2008/053283 patent/WO2008116806A1/en not_active Ceased
- 2008-03-19 DK DK08718009.7T patent/DK2124973T3/da active
- 2008-03-19 MX MX2009010244A patent/MX2009010244A/es not_active Application Discontinuation
- 2008-03-19 AR ARP080101138A patent/AR065791A1/es not_active Application Discontinuation
- 2008-03-19 MY MYPI20093944A patent/MY164520A/en unknown
- 2008-03-19 ES ES08718009.7T patent/ES2542694T3/es active Active
- 2008-03-19 BR BRPI0809258A patent/BRPI0809258B8/pt active IP Right Grant
- 2008-03-19 PT PT87180097T patent/PT2124973E/pt unknown
- 2008-03-19 PL PL08718009T patent/PL2124973T3/pl unknown
- 2008-03-19 AU AU2008231847A patent/AU2008231847B2/en active Active
- 2008-03-19 KR KR1020097022078A patent/KR101688656B1/ko active Active
- 2008-03-19 CA CA2681514A patent/CA2681514C/en active Active
- 2008-03-19 JP JP2010500223A patent/JP2010521534A/ja active Pending
- 2008-03-19 EP EP08718009.7A patent/EP2124973B1/en active Active
- 2008-03-19 NZ NZ579852A patent/NZ579852A/en not_active IP Right Cessation
- 2008-03-20 CL CL200800804A patent/CL2008000804A1/es unknown
- 2008-03-20 US US12/052,016 patent/US20080233182A1/en not_active Abandoned
- 2008-03-21 TW TW097110250A patent/TW200904456A/zh unknown
-
2009
- 2009-09-22 TN TNP2009000387A patent/TN2009000387A1/fr unknown
- 2009-09-22 GT GT200900251A patent/GT200900251A/es unknown
- 2009-09-22 IL IL201109A patent/IL201109A/en active IP Right Grant
- 2009-09-23 CO CO09103873A patent/CO6230993A2/es not_active Application Discontinuation
- 2009-10-02 MA MA32248A patent/MA31293B1/fr unknown
- 2009-10-23 EC EC2009009700A patent/ECSP099700A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR065791A1 (es) | 2009-07-01 |
| US20080233182A1 (en) | 2008-09-25 |
| BRPI0809258A2 (pt) | 2014-09-23 |
| MX2009010244A (es) | 2009-10-26 |
| MA31293B1 (fr) | 2010-04-01 |
| IL201109A0 (en) | 2010-05-17 |
| DK2124973T3 (da) | 2015-06-22 |
| KR101688656B1 (ko) | 2016-12-21 |
| EP2124973A1 (en) | 2009-12-02 |
| AU2008231847A1 (en) | 2008-10-02 |
| BRPI0809258B8 (pt) | 2021-05-25 |
| GT200900251A (es) | 2018-10-08 |
| CA2681514C (en) | 2016-11-08 |
| PT2124973E (pt) | 2015-09-01 |
| NZ579852A (en) | 2012-03-30 |
| JP2010521534A (ja) | 2010-06-24 |
| CA2681514A1 (en) | 2008-10-02 |
| MY164520A (en) | 2017-12-29 |
| PE20090186A1 (es) | 2009-03-20 |
| TN2009000387A1 (en) | 2010-12-31 |
| TW200904456A (en) | 2009-02-01 |
| IL201109A (en) | 2016-10-31 |
| PL2124973T3 (pl) | 2015-10-30 |
| AU2008231847B2 (en) | 2012-12-06 |
| EP2124973B1 (en) | 2015-05-27 |
| CO6230993A2 (es) | 2010-12-20 |
| BRPI0809258B1 (pt) | 2019-10-01 |
| RU2009139002A (ru) | 2011-04-27 |
| ES2542694T3 (es) | 2015-08-10 |
| ECSP099700A (es) | 2009-11-30 |
| WO2008116806A1 (en) | 2008-10-02 |
| KR20100015799A (ko) | 2010-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0814267A2 (pt) | Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico. | |
| CL2013001891A1 (es) | Compuestos heterociclicos fusionados; composicion farmaceutica y uso en el tratamiento de la degeneracion macular asociada con la edad. | |
| CL2007002513A1 (es) | Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras. | |
| BR112013011480A2 (pt) | método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer | |
| CL2013002083A1 (es) | Compuestos derivados de 2-amino-5-(trifluorometil)-furo[3,4-d]tiazina, como inhibidores de la produccion de la proteina beta-amiloide; composicion farmaceutica; y su uso para tratar o prevenir una enfermedad neurodegenerativa tal como demencia tipo alzheimer y demencia senil, y para tratar o prevenir la diabetes tipo 2. | |
| CL2008000789A1 (es) | Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras. | |
| CL2007003472A1 (es) | Sal fumarato de (alfa s,beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamie | |
| BRPI1012116A2 (pt) | composição farmacêutica para o tratamento de doenças cardíacas | |
| MX2008005853A (es) | Mezclas insecticidas sinergicas para el tratamiento de las semillas | |
| CL2008000403A1 (es) | Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos. | |
| CL2007003635A1 (es) | Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer. | |
| CL2007000806A1 (es) | Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| IL190695A (en) | Use of analogue compastatin to prepare a pharmaceutical composition for the treatment of macular degeneration | |
| CL2013000850A1 (es) | Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluoro-metil-piridin-2-amina y de la sal monoclorhidrato composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa como carcionoma de cerebro, de colon, leucemia, mieloma multiple, carcionoma mamario, entre otros. | |
| CL2007001427A1 (es) | Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po | |
| CL2007003609A1 (es) | Compuestos derivados de dihidropiridinas sustituidas; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; proceso para producir la composicion farmaceutica; y uso en el tratamiento de una enfermedad mejorada con la inhibicion | |
| LT3708178T (lt) | Peptidas, skirtas naudoti makulos degeneracijos prevencijai arba gydymui | |
| BRPI0818459A2 (pt) | Composição farmacêutica adequada para uso oftálmico. | |
| CL2007002669A1 (es) | Compuestos derivados de benzoxazol-2,7-disustituido y oxazol[5,4-c]-piridina; proceso de fabricacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad mediada por las cinasas jack2 y/o jack3 tal como cancer. | |
| PA8772101A1 (es) | Imidazol-triazolopirimidinas sustituidas | |
| BRPI1013763A2 (pt) | Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto | |
| IL204658A (en) | Pharmaceutical preparation for topical use in the form of an opaque gel-gel containing diclofenac diethylammonium salt | |
| BRPI0914410A2 (pt) | composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares. | |
| CL2007002919A1 (es) | Compuestos derivados de pirido[2,3-b]indol, inhibidores de quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar cancer, entre otras enfermedades. | |
| HN2009003424A (es) | (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea |